A Sphingosine Kinase-1 Inhibitor, SKI-II, Induces Growth Inhibition and Apoptosis in Human Gastric Cancer Cells

  • Li, Pei-Hua (Department of Otorhinolaryngology, Affiliated Hospital of Xuzhou Medical College) ;
  • Wu, Jin-Xia (Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College) ;
  • Zheng, Jun-Nian (Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College) ;
  • Pei, Dong-Sheng (Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College)
  • Published : 2015.01.06


SKI-II has been reported as an inhibitor of sphingosine kinase 1 and has been extensively used to prove the involvement of sphingosine kinase and sphingosine-1-phosphate (Sphk1) in cellular processes. In the current study, we investigated the effects of SKI-II and its potential mechanisms in human gastric cancer SGC7901 cells. After treatment with SKI-II, cell growth, cell cycle distribution, apoptosis, expression of Sphk1, NF-${\kappa}B$, Bcl-2, Bax and p27 were assessed by MTT assay, flow cytometry, electron microscopy, immunocytochemistry and Western-blot assay, respectively. Our results showed that SKI-II markedly inhibited SGC7901 cell survival in a dose-dependent manner, reduced cell proliferation with accumulation of cells in the G0/G1 phase and induced apoptosis in the tumor cells. Furthermore, Western blotting and immunocytochemistry showed that the expression of p27 and Bax was increased significantly, but the expression of NF-${\kappa}B$, Bcl-2 and Sphk1 decreased by different degrees. These results indicate that SKI-II induced cell growth arrest and apoptosis. The increased apoptotic sensitivity of SGC7901 was correlated with NF-${\kappa}B$ or Bcl-2/Bax activation.


Sphingosine kinase 1;SKI-II;proliferation;apoptosis;SGC7901 gastric cancer cells


Supported by : National Natural Science Foundation of China


  1. Abukhdeir AM, Park BH (2008). P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med, 10, 19.
  2. Cao Y, Karin M (2003). NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia, 8, 215-23.
  3. Cuvillier O (2008). Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets, 12, 1009-20.
  4. Dang Y, Wang YC, Huang QJ (2014). Microarray and nextgeneration sequencing to analyse gastric cancer. Asian Pac J Cancer Prev, 15, 8033-9.
  5. Esteban V, Lorenzo O, Ruperez M, et al (2004). Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol, 15, 1514-29.
  6. Fan TJ, Han LH, Cong RS, et al (2005). Caspase family proteases and apoptosis. Acta Biochim Biophys Sin, 37, 719-27.
  7. Gao H, He S, Tang WX, et al (2007). Inhibition of NF-kappa B activity enhanced apoptosis induced by matrine in hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi, 15, 914-7 (in Chinese).
  8. Grabsch HI, Tan P (2013). Gastric cancer pathology and underlying molecular mechanisms. Dig Surg, 30, 150-8.
  9. Herr DR, Chun J (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets, 8, 155-67.
  10. Kim N, Kim JE, Choung HK, et al (2014). Expression of cell cycle regulatory proteins in eyelid sebaceous gland carcinoma: low p27 expression predicts poor prognosis. Exp Eye Res, 118, 46-52.
  11. Kohno M, Momoi M, Oo ML, et al (2006). Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol, 26, 7211-23.
  12. Lee SY, Yuk DY, Song HS, et al (2008). Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur J Pharmacol, 582, 17-25.
  13. Li W, Yu CP, Xia JT, et al (2009). Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res, 15, 1393-9.
  14. Lin CF, Chen CL, Chang WT, et al (2005). Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J Biol Chem, 280, 23758-65.
  15. Martin JL, de Silva HC, Lin MZ, et al (2014). Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther, 13, 316-28.
  16. Sankala HM, Hait NC, Paugh SW, et al (2007). Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res, 67, 10466-74.
  17. Sasaki N, Morisaki T, Hashizume K, et al (2001). Nuclear factorkappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res, 7, 4136-42.
  18. Shida D, Takabe K, Kapitonov D, et al (2008). Targeting SphK1 as a new strategy against cancer. Curr Drug Targets, 9, 662-73.
  19. Shishodia S, Aggarwal BB (2004). Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res, 119, 139-73.
  20. Taha TA, Hannun YA, Obeid LM (2006). Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol, 39, 113-31.
  21. Tohdo H, Yokozaki H, Haruma K, et al (1993). p53 gene mutations in gastric adenomas. Virchows Arch B Cell Pathol Incl Mol Pathol, 63, 191-5.
  22. Xie Z, Koyama T, Suzuki J, et al (2001). Coronary reperfusion following ischemia: different expression of bcl-2 and bax proteins, and cardiomyocyte apoptosis. Jpn Heart J, 42, 759-70.
  23. Yang YL, Ji C, Cheng L, et al (2012). Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci, 103, 1538-45.
  24. Zhang C, He H, Zhang H, et al (2013). The blockage of Ras/ ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells. Biochem Biophys Res Commun, 434, 35-41.
  25. Zhu Z-A, Zhu Z-Q, Cai H-X, et al (2012). Reversion of multidrug resistance by SKI-II in SGC7901/DDP cells and exploration of underlying mechanisms. Asian Pac J Cancer Prev, 13, 625-31.

Cited by

  1. Activation of SphK1 by K6PC-5 Inhibits Oxygen–Glucose Deprivation/Reoxygenation-Induced Myocardial Cell Death vol.34, pp.11, 2015,